Table 2.
Rowachol (n = 71) | Placebo (n = 67) | P | |
---|---|---|---|
Age in years | 51.5 ± 15.6 | 48.0 ± 13.8 | 0.21 |
Gender (male: female) | 26: 45 | 33: 34 | 0.13 |
BMI (kg/m2) | 24.6 ± 3.7 | 25.2 ± 3.5 | 0.90 |
ASA class (minimal/moderate/severe) | 46/25/0 | 43/24/0 | 0.94 |
Preoperative ERCP stone removal | 8 (11.3) | 6 (9.0) | 0.65 |
GB stone | 66 (93.0) | 62 (92.5) | 0.81 |
aCombined comorbid diseases | 22 (31.2) | 21 (31.3) | 0.96 |
Single port cholecystectomy | 5 (7.0) | 7 (10.4) | 0.48 |
Difficulty score in LC | 0.5 ± 1.0 | 0.8 ± 1.2 | 0.54 |
bPostoperative complication | 0 | 1 (1.5) | 0.49 |
Open conversions | 0 | 0 | 1.00 |
cPathology (acute: chronic) | 6: 61 | 13: 53 | 0.17 |
Operative time (min) | 51.9 ± 27.2 | 58.8 ± 30.0 | 0.14 |
Values denote mean values ± standard deviation or no. (%) of patients.
BMI indicates body mass index; ASA, American Society of Anesthesiologists; ERCP, Endoscopic Retrograde Cholangiopancreatography; LC, laparoscopic cholecystectomy.
Cardiovascular, Cerebrovascular, Diabetes mellitus, Chronic obstructive lung disease, Chronic renal failure, etc.
1 case of minor bile leak only, no other complication occurred.
3 cases xanthogranulomatous cholecystitis, 2 cases T1 GB cancer.